Trending Topics in Gastroenterology | GastroAGI

Barrett’s esophagus with indefinite dysplasia(GIE, Jan-2026)

Barrett’s esophagus with indefinite dysplasia (IND) represents a challenging diagnostic category, characterized by histologic uncertainty between nondysplastic Barrett’s esophagus and low-grade dysplasia. This ambiguity often arises due to overlapping features and confounding factors such as inflammation or technical issues during biopsy interpretation. IND is considered a "gray zone" diagnosis with significant variability in pathologic interpretation among different pathologists, leading to inconsistent clinical management. Patients with IND are at risk of harboring undetected dysplasia, underscoring the importance of early re-evaluation through repeat endoscopy after optimizing acid suppression. Persistent IND over time signals a meaningful risk of progression to higher-grade dysplasia or esophageal adenocarcinoma, necessitating careful surveillance and potentially more aggressive management strategies. High-quality endoscopic techniques, systematic biopsy protocols, and improved training for endoscopists are critical to reducing missed dysplasia and ensuring accurate diagnosis. Emerging technologies, such as artificial intelligence-based computer-aided detection systems, show promise in enhancing the recognition of Barrett’s-related neoplasia. Additionally, risk stratification beyond histology, incorporating clinical factors and biomarkers, may help identify IND patients at highest risk for progression. Given the progression risk comparable to low-grade dysplasia, closer surveillance and selective therapeutic interventions are increasingly justified for patients with IND to mitigate the risk of advanced disease.

EREFS as a Clinical Trial Endpoint in Eosinophilic Oesophagitis

**Introduction:** Eosinophilic oesophagitis (EoE) is a chronic immune-mediated condition that significantly contributes to upper gastrointestinal morbidity. Historically, clinical trials evaluating treatments for EoE have relied on two co-primary endpoints: symptom improvement and histologic assessment, primarily measured by peak eosinophil count (PEC). While PEC has been widely used as an objective biomarker of disease activity, it has limitations in fully capturing the global severity and activity of EoE. Endoscopic evaluation, particularly through the Hirano EoE Endoscopic Reference Score (EREFS), has emerged as a promising outcome metric that offers a more comprehensive assessment of disease activity. This review explores the potential of EREFS as a "trial-ready" endpoint, alongside or in place of PEC, in clinical trials for EoE. --- **Problem Statement:** The current reliance on PEC as a primary histologic endpoint in EoE clinical trials may not fully encapsulate the complexity of disease activity or its impact on the oesophagus. PEC provides a snapshot of eosinophilic infiltration but does not reflect structural changes, complications, or the broader severity of the disease. On the other hand, endoscopic findings, as classified by the EREFS system, provide a standardized and validated method to assess key oesophageal features such as rings, furrows, exudates, edema, and strictures. EREFS has demonstrated accuracy, responsiveness, and clinical relevance, making it a strong candidate for inclusion as a co-primary or standalone endpoint in EoE trials. However, its integration into clinical trials requires further exploration and consensus on defined thresholds for response and its association with clinically meaningful outcomes. --- **Conclusion:** The Hirano EoE Endoscopic Reference Score (EREFS) offers a validated and standardized approach to assessing oesophageal disease activity and severity in eosinophilic oesophagitis. Evidence supports its accuracy, responsiveness to therapy, and clinical relevance, making it a viable and "trial-ready" endpoint for clinical trials. While PEC remains an important measure of histologic response, EREFS provides a complementary perspective that encompasses structural and functional changes in the oesophagus. Incorporating EREFS as a co-primary biologic endpoint in EoE trials could enhance the evaluation of therapeutic efficacy and provide a more comprehensive understanding of disease activity. This approach has the potential to improve clinical care and advance the development of effective treatments for EoE.

First genome-wide association study and idiopathic achalasia

**Introduction:** Idiopathic achalasia (IA) is a rare disorder where the neurons in the myenteric plexus degenerate, causing irreversible esophageal dysfunction. While immune-mediated mechanisms have been suggested as a cause, the exact reasons for IA remain unclear. To address this, researchers conducted the first genome-wide association study (GWAS) to explore the genetic factors contributing to IA. This study analyzed genetic data from 4,602 European patients with IA and compared it to 10,766 ethnically-matched controls. **Problem Statement:** The study aimed to uncover the genetic risk architecture of IA by identifying specific genetic variants (SNPs) and mechanisms linked to the disease. The researchers focused on the role of the HLA (human leukocyte antigen) region, as well as other genetic variants outside the HLA locus, to better understand IA's underlying biology. **Conclusion:** The study revealed that variations in the HLA-DQB1 gene, specifically an 8-amino acid insertion, are strongly associated with IA risk. Additional genetic associations were found in HLA-DQα1, HLA-DQβ1, and HLA-DRβ1 positions, highlighting the importance of HLA class II genes in IA. Outside the HLA region, three genetic variants were linked to IA, including one affecting immune-related genes like PTPN22 and TNFSF8. The findings also showed shared genetic risk between IA and Crohn’s disease, and identified memory T-cells (FOS+Tc4+CD8+) as central to IA development. This groundbreaking study provides new insights into IA’s genetic and immune-related mechanisms, paving the way for better understanding and potential therapeutic strategies.

Magnetically controlled capsule endoscopy and Gastric conditions

Magnetically Controlled Capsule Endoscopy (MCE) is an innovative, noninvasive diagnostic technology designed to evaluate gastric conditions as an alternative to the traditional esophagogastroduodenoscopy (EGD). EGD, although highly accurate, is an invasive procedure requiring sedation and the insertion of an endoscope, which can cause discomfort and potential risks for patients. MCE, on the other hand, involves swallowing a small capsule equipped with a camera that captures high-resolution images of the gastrointestinal tract. The capsule's movement is controlled externally using magnetic fields, allowing for thorough visualization of gastric anatomy without the need for invasive intervention. A recent review aimed to assess the diagnostic accuracy of MCE compared to EGD, which is considered the gold standard for detecting gastric conditions. The analysis included ten studies with a total of 1,667 diagnostic units, and the findings demonstrated that MCE has a high diagnostic accuracy. The pooled sensitivity and specificity of MCE were both 0.92, indicating its ability to correctly identify both the presence and absence of gastric abnormalities. The area under the receiver operating characteristic curve (AUC) was 0.96, reflecting excellent diagnostic performance. Furthermore, the diagnostic odds ratio (DOR) of 129 suggests that MCE is highly effective at distinguishing between diseased and non-diseased states. Despite its promising results, substantial heterogeneity (I² = 97%) was observed across studies, particularly in specificity, highlighting the need for further standardization and research. MCE offers significant potential as a noninvasive alternative to EGD, especially for patients who cannot tolerate traditional endoscopy. Future studies should focus on optimizing its clinical application, addressing interstudy variability, and evaluating its cost-effectiveness to establish its role in routine clinical practice.

Endoscopy and Celiac Disease

Endoscopy plays a crucial role in diagnosing celiac disease, a condition characterized by damage to the small intestinal lining, specifically villous atrophy (VA). Villous atrophy refers to the flattening or loss of the tiny finger-like projections (villi) in the small intestine, which are essential for nutrient absorption. Identifying VA is a key diagnostic step for celiac disease, and this is typically confirmed through duodenal biopsies taken during endoscopy. Endoscopic techniques have evolved to help in detecting VA more effectively. While standard white-light endoscopy is commonly used, it has limitations in sensitivity, meaning it may miss subtle or patchy lesions. Advanced endoscopic techniques, however, have shown improved accuracy in identifying these changes. Key advanced techniques include: 1. **Water Immersion Technique**: This method involves immersing the area with water during the procedure, enhancing visibility. It has demonstrated excellent sensitivity and specificity, making it highly effective in detecting VA. 2. **Narrow Band Imaging (NBI)**: This technique uses specific wavelengths of light to enhance the visualization of mucosal and vascular patterns. It has shown high accuracy in identifying villous atrophy. 3. **Dye-Based Chromoendoscopy**: By applying dyes to the intestinal lining during endoscopy, this method highlights abnormalities and improves the detection of subtle lesions. 4. **White Light Magnification Endoscopy**: This technique magnifies the intestinal surface for better visualization. While it has good sensitivity, its specificity is relatively lower compared to other advanced techniques. 5. **Confocal Endomicroscopy**: This is a highly advanced imaging method that provides microscopic views of the intestinal lining in real-time. It has shown good sensitivity and specificity for detecting VA. 6. **i-Scan**: A digital enhancement technology that improves mucosal visualization. Its performance is similar to standard white-light endoscopy but with slightly lower specificity. Overall, advanced endoscopic techniques like water immersion, narrow band imaging, and dye-based chromoendoscopy are particularly effective in detecting subtle or patchy lesions that might be missed by standard white-light endoscopy. These methods offer improved sensitivity and specificity, aiding in more accurate and reliable diagnosis of celiac disease. Endoscopy, combined with targeted biopsies, remains a cornerstone of diagnosing celiac disease, especially in cases where symptoms or blood tests suggest the condition.

Low FODMAP and Functional Dyspepsia

The low FODMAP diet (LFD) has emerged as a promising dietary intervention for individuals suffering from functional dyspepsia (FD), a common gastrointestinal disorder characterized by symptoms such as postprandial distress, bloating, and epigastric pain. Recent research has shed light on the potential role of increased duodenal mucosal permeability in the pathophysiology of FD, with adverse reactions to certain nutrients being a key underlying mechanism. One such group of nutrients implicated in symptom exacerbation is fermentable oligo-, di-, monosaccharides, and polyols (FODMAPs). ### Key Findings on Low FODMAP Diet and FD: 1. **Symptom Improvement:** - A 6-week adherence to a low FODMAP diet resulted in significant improvement in symptom severity for 73% of FD patients, as measured by the Leuven Postprandial Distress Syndrome (LPDS) daily diary. - Additional validated tools, such as the Short Form-Nepean Dyspepsia Index (SF-NDI), the Patient Assessment of Upper Gastrointestinal Symptoms (PAGI-SYM), and the Patient Health Questionnaire (PHQ), also showed significant improvement in symptom scores during the LFD. 2. **Duodenal Mucosal Permeability:** - While the LFD improved symptoms, it was not associated with significant changes in mucosal integrity, as measured by transepithelial electrical resistance (TEER) and dextran flux in duodenal biopsies. - Interestingly, there was a positive correlation between changes in TEER and symptom improvement (delta TEER correlated positively with delta LPDS), suggesting that mucosal integrity may still play a role in symptom modulation for some patients. 3. **FODMAP Reintroduction and Individual Triggers:** - Following the LFD, patients underwent a blinded reintroduction phase where they were challenged with various FODMAP powders, including fructans, fructose, galacto-oligosaccharides (GOS), lactose, mannitol, sorbitol, and glucose. - A wide variety of FODMAPs were found to trigger symptoms, with mannitol being the most common trigger (23% of cases). - Interestingly, 27% of patients experienced symptom exacerbation even with glucose, which is not classified as a FODMAP, pointing to individual variations in nutrient sensitivity. ### Implications: - The study highlights that a low FODMAP diet can be an effective strategy for managing symptoms in FD patients. However, the response to individual FODMAPs varies significantly, underscoring the need for personalized dietary approaches. - The findings also suggest that while mucosal integrity is not universally altered in FD, it may still play a role in symptom generation for a subset of patients. - The unexpected symptom provocation by glucose in some individuals raises questions about other potential mechanisms, such as visceral hypersensitivity or altered gut-brain signaling, which warrant further investigation. ### Conclusion: A low FODMAP diet offers significant symptom relief for many FD patients, though the underlying mechanisms may not be solely related to mucosal permeability. Individualized reintroduction of FODMAPs is crucial to identify specific triggers and optimize dietary management. Further research is needed to explore the complex interplay of dietary factors, mucosal integrity, and symptom generation in functional dyspepsia.

Proton Pump Inhibitors and Gastric Cancer Risk: A Systematic Review

The systematic review and evidence synthesis you referred to evaluates the long-debated association between proton pump inhibitor (PPI) use and gastric cancer risk. It aims to assess potential causality through a life course epidemiology framework. Here's a detailed summary of the findings: ### **Overview of the Evidence** The review includes a comprehensive analysis of studies up to October 2024, examining the relationship between PPI use and gastric cancer risk in humans. The evidence base consists of: - **33 original studies** - **21 meta-analyses** - **Three umbrella meta-analyses** - **One individual patient data meta-analysis** - **One Markov model** ### **Key Findings** 1. **Association Between PPI Use and Gastric Cancer Risk**: - Across the studies, PPIs were consistently associated with an increased risk of gastric cancer. - Out of 21 meta-analyses, 20 reported pooled relative risks (RRs) ranging from approximately **1.3 to 2.9**, indicating a significant association. 2. **Challenges in Interpretation**: - **Confounding by indication**: Patients prescribed PPIs often have underlying conditions that may themselves increase gastric cancer risk. - **Reverse causation**: Gastric cancer symptoms may lead to PPI prescriptions, rather than PPIs causing cancer. - **Insufficient lag time**: Many studies did not account for the time required for cancer to develop. - **Helicobacter pylori infection and eradication therapy**: It was difficult to separate the effects of PPIs from those of H. pylori eradication therapies, which are also linked to gastric cancer risk. 3. **Consistency Across Study Designs**: - Despite methodological challenges, the association between PPI use and gastric cancer risk remained consistent across different study designs, populations, and analytical approaches. ### **Life Course Epidemiology Framework** The authors propose a "sensitive period" model, suggesting that exposure to PPIs during early life, childhood, or young adulthood may pose greater long-term gastric cancer risk compared to exposure later in life. Supporting evidence includes: - Exploratory analyses of Swedish cancer incidence data showing: - Declining overall gastric cancer rates since 1970. - Increasing incidence among younger men (<40 years) starting in the early 2000s, which aligns with widespread PPI use and Helicobacter pylori eradication strategies. ### **Implications for Prescribing Practices** - **Older Adults**: In older adults with clear indications for PPI use (e.g., gastroesophageal reflux disease or peptic ulcers), the gastric cancer risk may be limited. - **Younger Populations**: The widespread and often unwarranted long-term use of PPIs in younger populations raises concern, given the potential long-term risk of gastric cancer. - **Caution in Prescribing**: - The study underscores the need for a more cautious, evidence-based approach to prescribing PPIs. - Avoiding unnecessary long-term PPI use, especially in younger individuals, is recommended. ### **Conclusion** This systematic review highlights a consistent association between PPI use and increased gastric cancer risk, particularly when exposure occurs during sensitive periods of life. While the risk may be limited in older adults with clear indications for PPI use, the findings suggest that unwarranted long-term use—especially in younger populations—should be minimized. Healthcare providers are encouraged to adopt a more cautious and evidence-based prescribing approach to mitigate potential risks. Let me know if you'd like further clarification or additional details!

Impact of pH Impedance Monitoring on Management of Proven vs Unproven GERD

The study highlights the differing impacts of pH-impedance monitoring on the management of patients with *proven* versus *unproven* gastroesophageal reflux disease (GERD). Below is a detailed breakdown of the findings: ### 1. **Proven GERD (Diagnosed Off-PPI Testing)** - **Off-PPI Testing as the Gold Standard**: The study found that off-PPI wireless pH monitoring remains the foundational diagnostic tool for identifying GERD. Patients with proven GERD off PPI had clear evidence of abnormal acid exposure that confirmed the diagnosis. - **On-PPI pH-Impedance Monitoring in Proven GERD**: - For patients with proven GERD, on-PPI pH-impedance monitoring could help identify those with *refractory GERD*—persistent reflux symptoms despite optimized PPI therapy. - However, it was noted that even in these patients, on-PPI testing often failed to show conclusive evidence of GERD, as more than half of patients with proven GERD off PPI showed no conclusive GERD evidence during on-PPI testing. - **Management Implications**: - On-PPI pH-impedance testing may have limited utility in guiding PPI management decisions for patients with previously proven GERD. - Off-PPI acid exposure time modestly predicted refractory GERD on PPI, reinforcing the importance of off-PPI testing in guiding treatment strategies. ### 2. **Unproven GERD (No Clear Diagnosis Off-PPI Testing)** - **On-PPI Testing in Unproven GERD**: - The study demonstrated that on-PPI pH-impedance monitoring does not add significant diagnostic or management value in patients with unproven GERD. - None of the on-PPI pH-impedance metrics (e.g., acid exposure time, reflux episodes, symptom association) were predictive of PPI management decisions. - Relying solely on on-PPI pH-impedance testing would miss a substantial proportion of true GERD cases because these patients may not show conclusive evidence of GERD while on PPI therapy. - **Management Implications**: - On-PPI pH-impedance testing should not be used as a primary diagnostic tool in patients with unproven GERD. - These patients should undergo off-PPI testing first to establish a definitive GERD diagnosis before considering PPI therapy or further evaluation of refractory symptoms. ### 3. **Key Takeaways on Management Decisions** - **Proven GERD**: On-PPI pH-impedance testing may be helpful in identifying refractory GERD, but its utility is limited, and off-PPI testing remains more predictive of GERD status and treatment response. - **Unproven GERD**: On-PPI pH-impedance monitoring is not useful as a primary diagnostic tool. Diagnosis and management decisions should rely on off-PPI testing to confirm GERD. ### 4. **Overall Conclusion** On-PPI pH-impedance monitoring has limited utility in managing GERD patients, particularly those with unproven GERD. It should not replace off-PPI testing as the primary diagnostic strategy. Instead, it should be reserved for select cases of refractory GERD in patients with previously documented GERD who continue to experience symptoms despite optimized PPI therapy.

Long-term treatment of EoE: BOS, BOT, and PPIs

Long-term treatment of Eosinophilic Esophagitis (EoE) focuses on preventing relapse and complications like fibrostenosis by maintaining remission through sustained therapy. Recent studies have evaluated three main therapeutic options: **Budesonide Oral Suspension (BOS)**, **Budesonide Orodispersible Tablets (BOT)**, and **Proton Pump Inhibitors (PPIs)**. Here’s a detailed breakdown of their efficacy and safety: --- ### **1. Budesonide Oral Suspension (BOS):** - **Efficacy**: A four-year U.S. multicenter open-label continuation study demonstrated that BOS maintained remission in over 50% of treated patients with EoE. - **Safety**: - Some evidence of adrenal suppression was observed, which is a potential side effect of corticosteroids. - Bone mineral density remained stable in adolescents, suggesting that BOS did not significantly affect bone health over the study period. - Mild esophageal candidiasis was reported as a side effect in some patients. --- ### **2. Budesonide Orodispersible Tablets (BOT):** - **Efficacy**: A three-year European study found BOT to be highly effective, maintaining remission in a greater proportion of patients compared to BOS. - **Safety**: - Minimal cortisol suppression was observed, indicating a lower risk of systemic corticosteroid side effects compared to BOS. - Similar to BOS, mild esophageal candidiasis was reported in some cases. --- ### **3. Proton Pump Inhibitors (PPIs):** - **Efficacy**: An updated systematic review showed that PPIs achieved remission in a substantial number of patients with EoE. PPIs are thought to work by reducing esophageal acid exposure and possibly through anti-inflammatory mechanisms. - **Maintenance**: Dose tapering was found to successfully maintain remission in most responders, making PPIs a viable long-term strategy for many patients. - **Safety**: PPIs are generally well-tolerated, with fewer systemic side effects compared to corticosteroids. --- ### **Key Insights from the Studies:** - **Effectiveness**: Both BOS and BOT are effective in maintaining long-term remission in EoE, with BOT showing slightly better outcomes in terms of remission rates and lower cortisol suppression. - **Side Effects**: Mild esophageal candidiasis is a common side effect of both BOS and BOT, while PPIs are associated with fewer side effects overall. - **Patient Monitoring**: Long-term therapy requires ongoing monitoring, especially in younger populations, to assess for potential side effects like adrenal suppression or bone health concerns. - **Non-Responders**: For patients who do not respond to these therapies, alternative strategies remain a clinical priority. --- ### **Clinical Implications:** - **Treatment Personalization**: The choice between BOS, BOT, and PPIs should be individualized based on patient response, safety profiles, and preferences. - **Safety Monitoring**: Regular monitoring for potential adverse effects, such as adrenal suppression, bone density changes, and esophageal candidiasis, is crucial, particularly in younger patients. - **Research Priorities**: Further studies are needed to explore alternative treatments for non-responders and to optimize long-term management strategies. --- In summary, BOS, BOT, and PPIs are all effective options for the long-term management of EoE, with each therapy offering distinct benefits and risks. BOT appears to have a slight advantage in terms of efficacy and safety over BOS, while PPIs provide a non-corticosteroid alternative with good remission rates and minimal side effects.

GLP-1 agonist, DM and GI safety - Real World Data

GLP-1 receptor agonists are a class of medications commonly used for the treatment of type 2 diabetes mellitus (DM) and, more recently, for obesity management. These drugs work by mimicking the action of the hormone glucagon-like peptide-1 (GLP-1), which helps regulate blood sugar levels by enhancing insulin secretion, suppressing glucagon release, slowing gastric emptying, and promoting satiety. ### Gastrointestinal (GI) Safety of GLP-1 Agonists in Type 2 Diabetes A recent large real-world study published in *Annals of Internal Medicine* focused on the gastrointestinal (GI) safety of three GLP-1 receptor agonists—**dulaglutide**, **semaglutide**, and **tirzepatide**—in adults with type 2 diabetes. The study analyzed data from over 130,000 matched patient pairs using Optum’s Clinformatics database, comparing these drugs head-to-head and against a different class of diabetes medications, **SGLT2 inhibitors**. #### Key Findings: 1. **Similar GI Safety Profiles Among GLP-1 Agonists**: - When dulaglutide, semaglutide, and tirzepatide were compared directly, they showed **no significant differences** in the risk of serious GI events. - Hazard ratios (HR) for severe GI events were: - **Tirzepatide vs. Dulaglutide**: HR 0.96 - **Semaglutide vs. Dulaglutide**: HR 0.96 - **Tirzepatide vs. Semaglutide**: HR 1.07 - These findings suggest that all three drugs carry **comparable levels of GI risk** when used in routine clinical practice. 2. **Higher GI Risk Compared to SGLT2 Inhibitors**: - When each GLP-1 agonist was compared to SGLT2 inhibitors, all three showed a **higher risk of GI adverse events**: - **Tirzepatide**: HR 1.53 - **Dulaglutide**: HR 1.36 - **Semaglutide**: HR 1.22 - The increased risk was primarily attributed to **GI motility-related issues**, such as delayed gastric emptying. This effect is a known physiological consequence of GLP-1 and GIP hormone stimulation. 3. **Types of Serious GI Events Studied**: - The study assessed a composite of serious GI events, including: - Bowel obstruction - Gastroparesis (delayed stomach emptying) - Pancreatitis - Biliary disease - Severe constipation - Despite these risks, the differences within the GLP-1 class were minimal, reassuring clinicians about the safety of these treatments. #### Clinical Implications: - **GLP-1 Agonists in Routine Practice**: - Clinicians can feel confident that dulaglutide, semaglutide, and tirzepatide have **similar GI safety profiles** and can be used interchangeably based on patient-specific factors such as efficacy, weight loss benefits, and tolerability. - **Comparison to SGLT2 Inhibitors**: - While GLP-1 agonists are associated with higher GI risks than SGLT2 inhibitors, these risks are generally manageable and expected due to the mechanism of action of GLP-1 receptor agonists. - **Monitoring and Counseling**: - Patients on GLP-1 agonists should be counseled about potential GI side effects, including nausea, vomiting, and constipation, which are common but often transient. - Clinicians should monitor for more serious GI events, especially in patients with pre-existing GI conditions like gastroparesis. #### Limitations of the Study: - The study relied on diagnostic codes from electronic health records, which may lead to **underreporting or misclassification** of GI events. - Uncontrolled confounding factors could influence the results, and the data may not fully capture all real-world adverse events. - The findings primarily apply to patients with type 2 diabetes and may not fully extend to individuals using these drugs for obesity treatment without diabetes. ### Conclusion: GLP-1 receptor agonists (dulaglutide, semaglutide, tirzepatide) are effective treatments for type 2 diabetes and obesity, with **similar GI safety profiles** within the class. However, they carry a **higher risk of GI adverse events** compared to SGLT2 inhibitors, driven mainly by delayed gastric emptying. Clinicians should consider these risks when prescribing GLP-1 agonists and provide appropriate monitoring and patient education. Ongoing studies and post-marketing surveillance are essential as these drugs are increasingly used in broader populations, including non-diabetic individuals for obesity management.